Page results
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia.
-
Myelodysplastic syndrome (MDS), or myelodysplasia, is a blood disorder that causes a drop in your number of healthy blood cells.
-
Our specialist myeloma team holds four myeloma outpatient clinics per week, seeing over 300 patients every month.
-
Myeloproliferative neoplasms (MPN) are disorders that affect how the body produces red blood cells, white blood cells, and platelets.
-
The Preterm Birth Clinic is one of a few UK specialist antenatal services that are designed specifically for the needs of pregnant women at risk of premature labour.
-
How to contact the London Sarcoma Service.
-
UCLH has welcomed its 1000th patient to our proton beam therapy department, which opened in December 2021.
-
Ibrahim Abubakar is Vice Provost (Health) and Professor of Infectious Disease Epidemiology at UCL. He is a member of the Global Preparedness Monitoring Board, University College London NHS Trust Board, UCL Partners Board and the Board of Resolve to Save Lives.
-
“Vaccines do not kill, the virus does”: that was the message from local leaders from a variety of different faiths during an event at the newly opened vaccination centre at the Business Design Centre in Islington.
-
Two directors have joined the UCLH Board – Liz O’Hara, director of workforce and Laura Churchward, director of strategy.
File results
-
FOI/2022/0551 - Procurement contact details
-
FOI/2022/0555 - Senior staff contact details
-
FOI/2022/0563 - Ambulatory cardiac monitoring
-
FOI/2022/0542 - Infection control audits from September 2020 to April 2021
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0559 - Proton Beam Therapy contract
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology